Abstract | BACKGROUND & AIMS:
Daclatasvir has achieved high sustained virologic response (SVR) rates in diverse hepatitis C virus (HCV) populations. This study evaluated the long-term efficacy and safety of daclatasvir-based regimens administered during clinical studies. METHODS: Patients enrolled within 6 months of parent study completion or protocol availability at the study sites. The primary objective was durability of SVR at follow-up Week 12 (SVR12). Secondary objectives included analysing HCV sequences in non-responders or responders who relapsed, and characterization of liver disease progression. RESULTS: Between 24 February 2012 and 17 July 2015, this study enrolled and began following 1503 recipients of daclatasvir-based regimens (follow-up cut-off, 13 October 2015); 60% were male, 18% aged ≥65 years, 87% had genotype-1a (42%) or -1b (45%) infection, and 18% had cirrhosis. Median follow-up from parent study follow-up Week 12 was 111 (range, 11-246) weeks. 1329/1489 evaluable patients were SVR12 responders; 1316/1329 maintained SVR until their latest visit. Twelve responders relapsed by (n = 9) or after (n = 3) parent study follow-up Week 24; one was reinfected. Relapse occurred in 3/842 (0.4%) and 9/487 (2%) responders treated with interferon-free or interferon-containing regimens, respectively. Hepatic disease progression and new hepatocellular carcinoma were diagnosed in 15 and 23 patients, respectively. Among non-responders, emergent non-structural protein-5A (NS5A) and -3 (NS3) substitutions were replaced by wild-type sequences in 27/157 (17%) and 35/47 (74%) patients, respectively. CONCLUSIONS:
|
Authors | K Rajender Reddy, Stanislas Pol, Paul J Thuluvath, Hiromitsu Kumada, Joji Toyota, Kazuaki Chayama, James Levin, Eric J Lawitz, Adrian Gadano, Wayne Ghesquiere, Guido Gerken, Maurizia R Brunetto, Cheng-Yuan Peng, Marcelo Silva, Simone I Strasser, Jeong Heo, Fiona McPhee, Zhaohui Liu, Rong Yang, Misti Linaberry, Stephanie Noviello |
Journal | Liver international : official journal of the International Association for the Study of the Liver
(Liver Int)
Vol. 38
Issue 5
Pg. 821-833
(05 2018)
ISSN: 1478-3231 [Electronic] United States |
PMID | 28941023
(Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't)
|
Copyright | © 2017 The Authors. Liver International Published by John Wiley & Sons Ltd. |
Chemical References |
- Antiviral Agents
- Carbamates
- Imidazoles
- Pyrrolidines
- RNA, Viral
- Valine
- daclatasvir
|
Topics |
- Adult
- Aged
- Antiviral Agents
(therapeutic use)
- Carbamates
- Disease Progression
- Drug Resistance, Viral
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Hepacivirus
- Hepatitis C, Chronic
(complications, drug therapy)
- Humans
- Imidazoles
(therapeutic use)
- Liver Cirrhosis
(virology)
- Male
- Middle Aged
- Pyrrolidines
- RNA, Viral
- Sustained Virologic Response
- Valine
(analogs & derivatives)
- Viral Load
- Young Adult
|